Mabwell Stages $547 Million IPO on STAR Board for Antibody Portfolio
publication date: Jan 20, 2022
Mabwell (Shanghai) Bioscience completed a $547 million IPO on Shanghai's STAR Board. Established in 2017, Mabwell is a clinical-stage antibody developer with 15 assets in its pipeline: three are in BLA stage, three in pivotal trials and six in Phase I/II trials. The company's lead candidates are biosimilars. It develops therapies for indications in auto-immune diseases, oncology, metabolic disorders, ophthalmologic diseases and infectious diseases. The company has a wholly-owned US subsidiary, Mabwell Therapeutics, in San Diego. Mabwell's shares have fallen 22% below their IPO price. More details....
Stock Symbol: (SHA: 688062)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.